The Buckingham Institute of Translational Medicine
The University of Buckingham
he Buckingham Institute of Translational Medicine is based within the Clore Laboratory and is an internationally recognised
research group led by Professors Mike Cawthorne and Jon Arch, researchers with a track record in drug discovery, including
beta3-adrenoceptor agonists for obesity, orexin and MCH-antagonists, and the insulin sensitiser drug rosiglitazone. Mike
Cawthorne was awarded the 2001 Society for Medicines Research Award for drug discovery in recognition of his work on the
discovery of rosiglitazone.
Our focus is encompassed by three research themes which highlight our combined basic research, drug discovery and clinical
expertise. The aim of our preclinical research is to inform drug development and enhance underlying biological understanding.
Through interaction with the medical school and our longstanding academic, clinical and pharmaceutical collaborations we are
translating our key research themes into clinical studies and ultimately therapeutics.
Diabetes, obesity and metabolic disease;
The Institute of Translational Medicine brings together drug discovery expertise, including chemoinformatics; basic science studies in
the areas of obesity, diabetes and metabolic disease; and dermatology studies, including cancer, bioinformatics and bioimaging.
The institute’s staff has more than 100 years of drug discovery experience in industry and has been at the forefront of drug discovery
in the metabolic disease area for decades.
The university has developed a medical school and the first students entered the MBChB programme in January 2015.